777TiP - Second interim analysis of the global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anticancer agents
Hepatobiliary Cancers
Biological Therapy
Presenter Bruno Daniele
Authors B. Daniele1, J. Turnes2, G. Bodoky3, C. Papandreou4, A. Hubert5, P. Stål6, V.A. Gorbunova7, F. Serejo8, A. Croitoru9, P. Mathurin10
  • 1Medical Oncology Unit, G. Rummo Hospital, 82100 - Benevento/IT
  • 2Gastroenterology Department, Hospital de Montecelo, 36071 - Pontevedra/ES
  • 3Department Of Oncology, St László Hospital, Budapest/HU
  • 4Department Of Medical Oncology, University Hospital of Larissa, 41110 - Larissa/GR
  • 5Gastrointestinal Cancer Center, Sharett Institute of Oncology, 91120 - Jerusalem/IL
  • 6Department Of Gastroenterology And Hepatology, Karolinska University Hospital, Stockholm/SE
  • 7Russian Scientific Research Oncology Centre, N. N. Blokhin Russian Cancer Research Center, RU-115478 - Moscow/RU
  • 8Center Of Gastroenterology, Liver Unit, Hospital de Santa Maria, Faculty of Medicine, Lisbon/PT
  • 9Hepatic Fundeni, FUNDENI Clinical Institute, Bucharest/RO
  • 10Service Des Maladies De L'appareil Digestif, Hôpital Claude Huriez, Lille/FR



GIDEON (NCT00812175) is an ongoing, global, prospective, non-interventional study of patients with unresectable hepatocellular carcinoma (HCC) receiving sorafenib (Nexavar®) in real-life practice. The aim is to evaluate sorafenib safety and efficacy in diverse settings and patient groups. The second interim analysis was triggered when ∼1500 patients had been treated for ≥ 4 months. We describe sorafenib use in Europe according to disease stage.


Patient/disease characteristics (including Barcelona Clinic Liver Cancer [BCLC], tumour node metastases [TNM], Cancer for the Liver Italian Programme [CLIP]) and treatment history were recorded at enrolment; sorafenib dose, concomitant medications, performance status, liver function, adverse events (AEs) and efficacy are recorded at follow-up visits.


Of 1571 patients in the safety population, 588 are in Europe (see table). The majority of patients were BCLC-C (52.9%), TNM III (40.3%) or CLIP 1/2 (26.0%/25.9%), although sorafenib was also used in patients with early, intermediate and end-stage disease. Generally, AEs and serious AEs (SAEs) increased with advancing disease (AEs: 66.0%, 87.4%, 85.5%, 89.7%; SAEs: 22.6%, 37.8%, 38.3%, 58.6%; for BCLC-A, B, C and D; respectively), whereas sorafenib-related AEs and SAEs were comparable across BCLC groups (AEs: 60.4%, 74.1%, 68.5%, 41.4%; SAEs: 7.5%, 15.4%, 10.3%, 10.3%; for BCLC-A, B, C and D; respectively). Evaluation will continue with more mature data.

Medical oncologist(n = 189) Hepatologist/GI specialist(n = 332) EU total(n = 588)
BCLC stage at study entry, % of n
A 6.9 8.7 9.0
B 19.6 27.7 24.3
C 59.3 50.6 52.9
D 3.2 5.4 4.9
NE/missing 11.1 7.5 8.8
TNM stage at study entry, % of n
I 3.2 10.5 8.8
II 8.5 12.3 10.2
III 39.2 41.9 40.3
IV 40.2 19.9 26.9
NE/missing 9.0 15.4 13.8
Child-Pugh score at start of sorafenib therapy, % of n
A 68.3 64.8 66.3
B 13.8 26.8 21.6
C 1.1 1.8 1.5
NE/missing 16.9 6.6 10.5
CLIP score at start of sorafenib therapy, % of n
0 14.8 8.4 11.9
1 24.3 26.5 26.0
2 24.3 26.5 25.9
3 5.8 15.7 11.4
4–6 4.2 11.4 8.7
NE/missing 26.5 11.4 16.2

NE, not evaluable


These data reflect real-world sorafenib given to a broad range of patients, indicating a similar safety profile across the different disease stages. Evaluation is ongoing, with more mature data expected from the final analysis.


B. Daniele: Dr B. Daniele has participated in advisory boards and received lecture fees from Bayer.

J. Turnes: Dr J Turnes has participated in advisory boards for Roche Pharma.

C. Papandreou: Prof. C Papandreou has participated in advisory boards for Bayer, Sanofi Aventis, Novartis, Bristol Meyers Squibb and Janssen.

P. Stål: Prof. Stål has advised and received a grant from Bayer.

A. Croitoru: Dr A Croitoru has consulted for and received an investigator fee from Bayer.

P: Mathurin: Dr. P . Mathurin was paid speaking at symposia for Roche, Schering-Plough, Gilead Sciences, Bristol-Myers Squibb, Janssen-Cilag and Bayer Healthcare pharmaceutical companies. He is an investigator for Roche, Schering-Plough, Bristol-Myers Squibb, Gilead Sciences, Vertex pharmaceuticals Janssen-Cilag, Boeringher, Novartis and Bayer Healthcare companies. He is a member of the French boards of experts in Hepatology for Roche Schering-Plough, Gilead Sciences, Bayer Healthcare and Bristol-Myers Squibb pharmaceutical companies. He is consulting for the Gilead Sciences, Bristol-Myers Squibb, Bayer Healthcare and Vertex pharmaceutical Companies.

All other authors have declared no conflicts of interest.